A new study from the U.K. examined COVID-19 vaccine efficacy among 175 patients with aplastic anemia and PNH. After a first vaccination, healthy volunteers had a seroconversion rate of 95%, compared ...

Patients who are taking complement inhibitors may still experience breakthrough hemolysis associated with respiratory viral infections. Patients with PNH should be closely monitored for signs of ...

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, potentially life-threatening disorder. It causes the red blood cells to break apart, a process called hemolysis. This releases hemoglobin from ...

The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta, Novartis), the first oral monotherapy for both treatment-naive and pretreated adults with paroxysmal nocturnal ...

A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes. Complement ...

The FDA approved iptacopan for treatment of adults with paroxysmal nocturnal hemoglobinuria. Iptacopan (Fabhalta, Novartis) is an oral selective complement factor B inhibitor designed to be given as ...

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare ...

Fewer than 50,000 people in the United States live with paroxysmal nocturnal hemoglobinuria (PNH). It’s a blood disease that impairs the production of red blood cells. PNH causes the destruction of ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder caused by a mutation in the PIGA gene. This mutation causes defective hematopoietic stem cells, which develop into defective red blood ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a very rare disease. It’s also very complex. If you or a loved one has recently been diagnosed with PNH, you may wonder what sort of challenges you will ...